Undetectable molecular residual disease after omacetaxine and nilotinib combination therapy in an imatinib-resistant chronic myeloid leukaemia patient harbouring the BCR-ABL1 T315I gatekeeper mutation.
Marie-Magdelaine
MM
Coude
Odile
O
Luycx
Marie-Estelle
ME
Cariou
Odile
O
Maarek
Hervé
H
Dombret
Jean-Michel
JM
Cayuela
Delphine
D
Rea
D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001549:Benzamides; D004351:Drug Resistance; D005260:Female; D006248:Harringtonines / Q000008:administration & dosage; D000077863:Homoharringtonine; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D009154:Mutation; D018365:Neoplasm, Residual; D010879:Piperazines / Q000627:therapeutic use; D011743:Pyrimidines / Q000008:administration & dosage / Q000627:therapeutic use
D001549:Benzamides; D006248:Harringtonines; D010879:Piperazines; D011743:Pyrimidines; D000077863:Homoharringtonine; D000068877:Imatinib Mesylate; C498826:nilotinib